Status:
COMPLETED
PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
GVHD, Acute
Eligibility:
All Genders
16-60 years
Phase:
PHASE2
Brief Summary
All patients received Flu-BU-VP16 as myeloablative conditioning followed by cyclophosphamide (D+3 and +4) and subsequent tacrolimus. For patients with unrelated or haplo-donor received low-dose ATG at...
Detailed Description
For patients with high-risk lymphoid malignancies, patients will undergo allo-HSCT from HLA matched sibling, unrelated (9\~10/10) donor or hallo-identical donors. For all patients will receive myeloab...
Eligibility Criteria
Inclusion
- patients with lymphoid malignancies: CR1 or CR2 for acute lymphoblastic leukemia; T cell lymphoma (any CR/PR); B cell lymphoma (PR1 or CR2), hodgkin's disease (CR2 or beyond), Sezary syndrome
- patients with HLA matched sibling, unrelated (HLA 9\~10/10 matched) or haplo-identical donor
Exclusion
- patients with active infection
- patients with abnormal liver function damage: ALT/AST above 2X normal range
- patients with abnormal renal function damage Scr\>160µmol/L;
- patients with insufficient pulmonary function (FEV1，FVC，DLCO\<50%）and heart failure or with EF \<50%)
- patients with mental instability
- unwilling to give inform consent
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2021
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT04118075
Start Date
January 1 2019
End Date
May 1 2021
Last Update
May 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rui Jin Hospital
Shanghai, Shanghai Municipality, China, 200025